![]() | ![]() |
Danish pharma giant Novo Nordisk plans to invest 5.4 billion Danish kroner ($747.2 million) into expanding its existing facilities in its hometown of Bagsværd, Denmark, a suburb of Copenhagen. Those plans also include the construction of a new plant.
The manufacturing of active pharmaceutical ingredients (API) is currently ongoing to support clinical trials. The expansions are expected to be finalised and fully operational in August of next year for purification. The new facility, which is centered around fermentation and recovery, is expected to be finalised in August 2024.
Novo Nordisk also plans to create more capacity for R&D activities and the production of APIs, mainly to supply its clinical trials as well as provide room for future development for its injectables and oral medicines, including in diabetes and obesity treatment space, according to the spokesperson.
Last news about this category
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy